Feb 05, 2016 at 15:10 | Source: CNBC-TV18
Ashish Kyal of wavesstrategy.com is of the view that one may stay invested in Sun Pharma.
Feb 05, 2016 at 12:15 | Source: CNBC-TV18
Deven Choksey of KRChoksey Investment Managers has a positive view on largecap pharma stocks and the cement space.
Feb 03, 2016 at 20:00 | Source: PTI
The company had posted a net loss of Rs 18.91 crore for the corresponding period of the previous fiscal, SPARC said in a BSE filing.
Feb 03, 2016 at 14:49 | Source: CNBC-TV18
CNBC-TV18's Ekta Batra lists out stocks that you should focus on Crompton Greaves, HUL, Cairn India, Vedanta, Hindalco, ICICI Bank, Sun Pharma.
Feb 03, 2016 at 08:44 | Source: CNBC-TV18
Stocks likely to be in focus are: DLF, Crompton Greaves, United Breweries, Tata Communications, Sun Pharmaceutical Industries, Amara Raja Batteries, Aurobindo Pharma, RPG Life Sciences, Majesco.
Feb 03, 2016 at 08:20 | Source: CNBC-TV18
Crompton Greaves | DLF | Adani Enterprises | GAIL | Sun TV Network | Tata Communications | Torrent Power | United Breweries | RPG Life | Tube Investments | Snowman Logistics | Oudh Sugar | Minda Industries | Uflex and Birla Corporation are stocks, which are in the news today.
Feb 02, 2016 at 15:07 | Source: CNBC-TV18
CNBC-TV18's Mangalam Maloo lists out stocks that you should focus on ICICI Bank, Axis Bank, Kotak Mahindra Bank, State Bank of India, Tech Mahindra, Sun Pharma, Cipla, Tata Steel, Hindalco, Cairn India, Vedanta, ONGC.
Feb 02, 2016 at 09:57 | Source: Moneycontrol.com
The company's subsidiary has received final approval for Imatinib Mesylate from Food and Drug Administration (FDA) in December 2015.
Feb 02, 2016 at 08:20 | Source: CNBC-TV18
Tata Motors | TVS Motor | DLF | Sun Pharma | Wipro | Tech Mahindra | Hero Motocorp | Balaji Telefilms | Maharashtra Seamless | Gujarat Siddhi | Shalimar Paints | EID Parry | Aban Offshore and State Bank Of Travancore are stocks, which are in the news today.
Feb 02, 2016 at 08:01 | Source: Reuters
Gleevec, or imatinib mesylate, costs up to about USD 90,000 annually in the United States, implying Sun's price could be roughly USD 60,000. Gleevec posted USD 4.7 billion in global revenue in 2015, and Swiss-based Novartis has said the US patent expiry puts around USD 2.5 billion in annual sales at risk.